Mekhjian HS, Phillips SF, Hofmann AF
Key safety signals observed in the Phase 2 trial included gastrointestinal adverse effects (nausea, vomiting, diarrhoea, and constipation), increases in resting heart rate, and gallbladder-related events consistent with the broader class of incretin-based therapies
Uraemic cardiomyopathy is characterized by myriad cardiac metabolic maladaptations, including altered mitochondrial function, changes in myocardial substrate utilization, altered metabolic transporter function and expression, and impaired insulin response and phosphoinositide-3 kinaseAKT signalling, which collectively lead to impaired cardiac energetics
No TEAEs were reported in the severe hepatic impairment group (Table 6)
Avoid overexertion, but staying active helps prepare your body for the metabolism-boosting effects of the injection
The formula contains pentadeca short-chain amino acids that may help support connective tissue and gut lining integrity